Johnson Pharmacare Limited has disclosed that it did not undertake any transactions with related parties during the financial year ended March 31, 2026. In a regulatory filing submitted to BSE on May 27, 2026, the company confirmed that while the provisions for Related Party Transactions (RPT) are applicable, no such transactions were entered into during the reporting period. Consequently, the disclosure of RPTs for the year is not applicable.

The filing was made pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015. The disclosure follows the format specified in SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021. The submission was signed by Nand Kishor Ray, Additional Director of the company.

The company provided a detailed table in the filing to declare the status of these transactions. The table covers various aspects, including details of the counterparty, the nature of the relationship, and the value of transactions. It also includes columns for financial indebtedness and details of loans or investments, should any have existed.

The table confirms that all relevant fields, including financial indebtedness, nature of loans, and interest rates, were nil for the period. This indicates that the company maintained no outstanding dues or financial engagements with related parties throughout FY26.

Johnson pharmacare Limited has strengthened its board of directors with two new appointments, as announced in a regulatory filing dated April 17, 2026. The pharmaceutical company's board meeting approved these strategic additions to enhance its leadership structure and operational capabilities.

Board Meeting Details

The board of directors convened on Friday, April 17, 2026, from 5:15 p.m. to 5:45 p.m. to deliberate on the director appointments. The meeting was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30 requirements.

New Director Appointments

The board approved two significant appointments effective immediately:

Director Profiles and Qualifications

Mr. Nand Kishore Ray brings experience to the board as the newly appointed Non-Executive & Non-Independent Director. Born on January 1, 1956, he is a graduate and son of Mr. Kalewar Ray. His appointment adds non-executive oversight to the company's governance structure.

Mr. Dheeraj Kumar joins as an Executive Director, bringing operational leadership to the board. Born on January 1, 2005, he is also a graduate and son of Mr. Nand Kishor Ray. His executive role will involve direct participation in the company's day-to-day management and strategic decisions.

Regulatory Compliance

Both appointees have submitted declarations of non-debarment as required under SEBI regulations. The declarations confirm that:

• Neither director is debarred from accessing capital markets
• No orders have been passed by SEBI or other authorities preventing them from holding director positions
• Both meet the eligibility criteria for their respective board positions

Corporate Governance Enhancement

These appointments reflect Johnson Pharmacare Limited's commitment to strengthening its corporate governance framework. The addition of both executive and non-executive directors provides a balanced approach to board composition, ensuring effective oversight while maintaining operational agility in the pharmaceutical sector.